Thymosin alpha 1 and HIV-1: Recent advances and future perspectives

Claudia Matteucci, Sandro Grelli, Emanuela Balestrieri, Antonella Minutolo, Ayele Argaw-Denboba, Beatrice Macchi, Paola Sinibaldi-Vallebona, Carlo Federico Perno, Antonio Mastino, Enrico Garaci

Research output: Contribution to journalReview articlepeer-review


In spite of the consistent benefits for HIV-1 infected patients undergoing antiretroviral therapy, a complete immune reconstitution is usually not achieved. Actually, antiretroviral therapy may be frequently accompanied by immunological unresponsiveness, persistent inflammatory conditions and inefficient cytotoxic T-cell response. Thymosin alpha 1 is a thymic peptide that demonstrates a peculiar ability to restore immune system homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.

Original languageEnglish
Pages (from-to)141-155
Number of pages15
JournalFuture Microbiology
Issue number2
Publication statusPublished - Feb 1 2017


  • ART
  • CD8 antiviral factor
  • HIV
  • immune dysfunction
  • immune reconstitution

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)


Dive into the research topics of 'Thymosin alpha 1 and HIV-1: Recent advances and future perspectives'. Together they form a unique fingerprint.

Cite this